The alteration in WNT4 gene expression tended to be more frequent in serous carcinomas (6 of 94 cases (6.38%); 4 cases—gene amplification; 1 case—deep deletion; 1 case—high mRNA; Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma Subtypes) than in EEC (7 of 329 (2.13%) cases; 1 case—mutation; 2 cases—gene amplification; 2 cases—deep deletion; 2—high mRNA; Uterine Endometrioid Carcinoma Subtypes) (Figure 5B). Here, WNT4 is linked to endometrioid adenocarcinoma.